$286 Million is the total value of Foresite Capital Management II, LLC's 11 reported holdings in Q4 2017. The portfolio turnover from Q3 2017 to Q4 2017 was 58.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| AIMT | Sell | Aimmune Therapeutics, Inc. | $117,248,000 | +23.8% | 3,100,146 | -18.9% | 40.96% | +6.7% |
| AERI | Aerie Pharmaceuticals, Inc. | $99,945,000 | +22.9% | 1,672,714 | 0.0% | 34.92% | +6.0% | |
| EPZM | Buy | Epizyme, Inc. | $19,554,000 | -33.5% | 1,558,108 | +1.0% | 6.83% | -42.7% |
| INSM | Buy | Insmed Incorporated | $16,171,000 | +72.7% | 518,645 | +72.9% | 5.65% | +48.9% |
| ALDR | Alder BioPharmaceuticals, Inc. | $11,952,000 | -6.5% | 1,043,832 | 0.0% | 4.18% | -19.4% | |
| XLRN | Acceleron Pharma Inc. | $10,387,000 | +13.7% | 244,756 | 0.0% | 3.63% | -2.0% | |
| DNLI | New | Denali Therapeutics Inc. | $3,910,000 | – | 250,000 | +100.0% | 1.37% | – |
| JUNO | Sell | Juno Therapeutics, Inc. | $3,885,000 | -3.8% | 85,000 | -5.6% | 1.36% | -17.1% |
| QURE | New | uniQure N.V. | $2,142,000 | – | 109,350 | +100.0% | 0.75% | – |
| LOXO | Sell | Loxo Oncology, Inc. | $1,002,000 | -23.9% | 11,900 | -16.8% | 0.35% | -34.5% |
| New | Alder BioPharmaceuticals, Inc.call | $40,000 | – | 24,000 | +100.0% | 0.01% | – | |
| ZFGN | Exit | Zafgen, Inc. | $0 | – | -30,775 | -100.0% | -0.04% | – |
| OREXQ | Exit | Orexigen Therapeutics, Inc. | $0 | – | -523,132 | -100.0% | -0.45% | – |
| DERM | Exit | Dermira, Inc. | $0 | – | -58,624 | -100.0% | -0.64% | – |
| JNCE | Exit | Jounce Therapeutics, Inc. | $0 | – | -119,912 | -100.0% | -0.76% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-02-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Epizyme, Inc. | 29 | Q4 2021 | 11.9% |
| Acceleron Pharma Inc. | 24 | Q3 2021 | 4.8% |
| Aerie Pharmaceuticals, Inc. | 22 | Q1 2020 | 40.3% |
| 10x Genomics, Inc. | 17 | Q3 2023 | 100.0% |
| Aimmune Therapeutics, Inc. | 17 | Q3 2019 | 41.0% |
| Alder BioPharmaceuticals, Inc. | 16 | Q3 2019 | 12.6% |
| Zafgen, Inc. | 12 | Q3 2017 | 33.5% |
| BioDelivery Sciences International, Inc. | 12 | Q1 2019 | 3.2% |
| Insmed Incorporated | 11 | Q1 2020 | 13.8% |
| Adaptimmune Therapeutics PLC | 9 | Q4 2018 | 11.3% |
View Foresite Capital Management II, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2023-11-13 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-12 |
| 13F-HR | 2023-02-13 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-12 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-11 |
| 13F-HR | 2021-11-12 |
| 13F-HR | 2021-08-16 |
View Foresite Capital Management II, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.